SRRA News and Press, Sierra Oncology Inc. From 01/31/22

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public...

Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 B. Riley Securities Oncology Investor Conference being held virtually from January 27-28, 20...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the pricing of an upsized underwritten public offering of 4,074,075 shares of its common stock and, in lieu of shares of common stock...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that it intends to offer and sell $100.0 million of shares of its common stock in an underwritten public offering. The proposed offer...

Sierra Oncology Inc. ( NASDAQ: SRRA ) shares are up 50% after the company announced a term loan deal with Oxford Finance LLC and the release of positive topline results from the vital Phase III MOMENTUM study. The MOMENTUM study , a global double-blind, randomized tr...

Shares of the clinical-stage biotech Sierra Oncology (NASDAQ: SRRA) jumped by as much as 90% in premarket trading Tuesday. Investors are piling into this small-cap biotech stock today in response to overwhelmingly positive late-stage trial results for the blood cancer drug candi...

—New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering target...

—Oxford Finance Debt Facility for up to $125 Million— —Series B Warrants Will Expire in 75 Days, and if Fully Exercised, Could Provide An Additional $33.3 Million— Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical compan...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the publication of a review article in the Journal of Hematology & Oncology that outlines the potential ability of momelotini...